Medico-economic Evaluation of IMRT by Hi Art, RapidArc, VMAT Therapy in Prostate, Cervix and Anal Canal Cancers

The aim of the study is a medico-economic evaluation to estimate a cost differential between three modalities of Intensity-Modulated Radiation Therapy for cancers of the prostate, cervix and anal canal with pelvic lymph node irradiation : treatment with helical Tomotherapy and dynamic arc therapy using two different technologies: RapidArc or VMAT.

Inclusion Criteria: * WHO performance index ≤ 2 * Age \> 18 years * Histologically confirmed carcinoma * Locally advanced anal canal cancer (\> 4 cm and/or N1 to N3), requiring irradiation of inguinal and pelvic lymph nodes with concomitant chemotherapy * Prostate cancer requiring pelvic lymph node irradiation and hormone therapy * Cervical cancer requiring irradiation of the pelvic lymph nodes, the primary tumor, and parametria with concomitant chemotherapy. Surgical resection may be performed after chemoradiotherapy depending on each center's practices. Boosts via external beam radiotherapy or brachytherapy are accepted * The investigator must ensure that the patient has not expressed its opposition to participate in this study. The signing of a consent form is optional; Exclusion Criteria: * History of invasive cancer (except basal cell carcinoma) * Indication for re-irradiation * Lombo-aortic lymph node irradiation * Postoperative radiotherapy * Geographic distance likely to interfere with patient follow-up